Research & Development
Abbott receives US FDA approval for its cardiac mapping platform EnSite X EP System with EnSite Omnipolar Technology
13 January 2022 -

Abbott (NYSE: ABT), a US-based global healthcare company, announced on Wednesday that it has received approval from the United States Food and Drug Administration (FDA) for the EnSite X EP System with EnSite Omnipolar Technology, a new cardiac mapping platform available in the United States and across Europe.

Abbott said that the system is designed to help physicians better treat abnormal heart rhythms called cardiac arrhythmias. Designed with input from electrophysiologists from around the world, the platform creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate. It includes Abbott's proprietary EnSite OT, which the company said uses the Advisor HD Grid Catheter to provide true electrograms regardless of how the catheter is oriented within the heart.

Mike Pederson, senior vice president, electrophysiology Abbott, said, 'As ablation therapy is increasingly used for patients battling cardiac arrhythmias, new, innovative and advanced cardiac mapping and imaging tools are essential to help physicians provide the best outcomes for their patients. We developed the EnSite X System with EnSite OT to enhance the utility of our unique Advisor HD Grid catheter and allow doctors to quickly and accurately create real-time, stable, three-dimensional models of the heart. These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue.'